Timothy S. Ernst - 30 Aug 2023 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Role
EVP, General Counsel & Sec
Signature
/s/ Timothy S. Ernst
Issuer symbol
BIO
Transactions as of
30 Aug 2023
Net transactions value
-$422,114
Form type
4
Filing time
31 Aug 2023, 14:00:55 UTC
Previous filing
23 Aug 2023
Next filing
06 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIO Bio-Rad A Common Stock Options Exercise $507,553 +2,350 +97% $215.98 4,766 30 Aug 2023 Direct
transaction BIO Bio-Rad A Common Stock Sale $154,117 -391 -8.2% $394.16 4,375 30 Aug 2023 Direct F1
transaction BIO Bio-Rad A Common Stock Sale $626,092 -1,582 -36% $395.76 2,793 30 Aug 2023 Direct F2
transaction BIO Bio-Rad A Common Stock Sale $149,458 -377 -13% $396.44 2,416 30 Aug 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIO Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,350 -100% $0.000000* 0 30 Aug 2023 Bio-Rad A Common Stock 2,350 $215.98 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $394.01 to $394.95, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $395.07 to $395.95, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $396.09 to $396.53, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option, representing a right to purchase a total of 2,500 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted.